Pfizer to keep pursuing M&A

Pfizer is rumored to be exploring the sale of a group of treatments in the cardiology and urology areas, generating a sales volume of at least $700m, in order to raise cash and streamline its portfolio, Bloomberg reported. According to analysts, the divestiture is likely to fetch Pfizer $2bn. In addition, the company said earlier this week that it is still looking for acquisition targets, despite the failed $160bn merger with Allergan and the $14bn acquisition of Medivation.
(Source Bloomberg)